Agios Pharmaceuticals (NASDAQ:AGIO) Rating Reiterated by Raymond James

Raymond James reaffirmed their outperform rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a report published on Thursday morning, Marketbeat reports. Raymond James currently has a $51.00 target price on the biopharmaceutical company’s stock.

Several other research firms also recently weighed in on AGIO. Leerink Partnrs downgraded shares of Agios Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Friday, September 27th. JPMorgan Chase & Co. reaffirmed a neutral rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, June 13th. Royal Bank of Canada reiterated an outperform rating and issued a $55.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, September 19th. StockNews.com cut Agios Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, August 5th. Finally, Leerink Partners lowered Agios Pharmaceuticals from an outperform rating to a market perform rating and lowered their target price for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of Hold and a consensus target price of $52.20.

Agios Pharmaceuticals Price Performance

Shares of Agios Pharmaceuticals stock opened at $42.65 on Thursday. The stock’s 50-day moving average is $44.59 and its 200 day moving average is $40.58. Agios Pharmaceuticals has a one year low of $19.80 and a one year high of $53.28. The firm has a market cap of $2.42 billion, a price-to-earnings ratio of -6.75 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The business had revenue of $8.60 million for the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. Agios Pharmaceuticals’s quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.51) earnings per share. On average, sell-side analysts expect that Agios Pharmaceuticals will post -4.87 EPS for the current fiscal year.

Insider Activity

In related news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the transaction, the chief executive officer now owns 78,792 shares in the company, valued at approximately $3,368,358. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of AGIO. Farallon Capital Management LLC grew its stake in Agios Pharmaceuticals by 34.1% in the 1st quarter. Farallon Capital Management LLC now owns 5,590,602 shares of the biopharmaceutical company’s stock valued at $163,469,000 after purchasing an additional 1,423,000 shares during the period. Marshall Wace LLP boosted its holdings in shares of Agios Pharmaceuticals by 307.8% in the 2nd quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock worth $48,887,000 after buying an additional 855,739 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Agios Pharmaceuticals by 23.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock valued at $58,861,000 after buying an additional 388,381 shares during the period. Frazier Life Sciences Management L.P. increased its holdings in Agios Pharmaceuticals by 66.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock worth $37,600,000 after buying an additional 348,808 shares during the last quarter. Finally, Candriam S.C.A. purchased a new stake in Agios Pharmaceuticals during the second quarter worth about $13,922,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.